www.EmploymentCrossing.com Washington State in $ 1,200,000 dollars as part of a solution of $ 60,000,000 with Pfizer for 33-state commercial practices potentially dangerous. The agreement ends a five-year investigation of allegations that the company marketed anti-inflammatory drugs Celebrex and Bextra for unapproved use, despite the known health risks. "This is not just deceptive marketing," off-label "marketing can create a potential risk to patients," Washington Attorney GeneralRob McKenna told the Seattle Post-Intelligencer. Settlement money can be used for attorneys' fees, enforcing consumer protection and education are used. The states alleged that despite significant safety concerns led the FDA to request a high-dose Bextra for acute pain and the market has declined surgery, Pfizer conducted an aggressive campaign to market the drug for any unauthorized purpose. The company provided prizes to encourage sales representatives to promote Bextra for off-label applications, corrupt influentialDoctors paid consultants and the weekend full of high-end resort and for the visits promoted Bextra off-label uses during educational programs for doctors. In the village, Pfizer will be required to seek FDA approval for the TV ads directed at consumers. New York, Pfizer leads globally in sales of pharmaceuticals. For more information on jobs in your area, go here.
Keywords: Washington, Seattle, Post-Intelligencer, Attorney, General, Rob, mckenna, Bextra, Pfizer, FDA
No comments:
Post a Comment